%0 Journal Article
%A Kurz, Carolin
%A Carli, Laura
%A Guersel, Selim
%A Schrurs, Isabelle
%A Jethwa, Alexander
%A Carboni, Margherita
%A Bittner, Tobias
%A Hortsch, Sayuri
%A Keeser, Daniel
%A Brendel, Matthias
%A Burow, Lena
%A Haeckert, Jan
%A Koriath, Carolin A M
%A Tatò, Maia Lucia
%A Utecht, Julia
%A Papazov, Boris
%A Morenas Rodriguez, Estrella
%A Pogarell, Oliver
%A Palleis, Carla
%A Weidinger, Endy
%A Stöcklein, Sophia
%A Levin, Johannes
%A Höglinger, Günter
%A Rauchmann, Boris-Stephan
%A Perneczky, Robert
%T Plasma biomarkers of amyloid, tau </td><td width="150">
%T amp; neuroinflammation in Alzheimer's disease and corticobasal syndrome.
%J Archiv für Psychiatrie und Nervenkrankheiten
%V 275
%N 8
%@ 1433-8491
%C Heidelberg
%I Springer
%M DZNE-2025-01313
%P 2255 - 2273
%D 2025
%X Blood-based biomarkers (BBBMs) could significantly facilitate the diagnosis of Alzheimer's disease (AD) and non-AD dementia by providing less invasive alternatives to cerebrospinal fluid (CSF) and positron emission tomography (PET) imaging.This study investigated how well the BBBMs-amyloid-β (Aβ) 1-42/1-40 ratio, phosphorylated tau181 (pTau181), apolipoprotein E4 (ApoE4), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL)-reflect thorough clinical work-up validated by PET and CSF biomarkers in participants with AD (n = 27), Aβ-negative CBS (n = 26), and agematched healthy controls (HC) (n = 17).Factor and correlation explored biomarker associations. Bayesian regression, backward selection regression, and ROC curve analysis were applied to identify optimal biomarker combinations and diagnostic cut-offs.In AD cases, pTau181 and ApoE4 levels were elevated, and the Aβ1-42/1-40 ratio was reduced. ROC analysis showed high accuracy for pTau181, ApoE4 and Aβ1-42/1-40 in discriminating AD from HC, with a combination significantly improving performance. However, limited fold change, and high variability reduced the diagnostic applicability of Aβ1-42/1-40 ratio. Elevated NfL levels were the most reliable biomarker for CBS-Aβ(-) cases. GFAP showed limited discriminatory power due to overlapping levels, suggesting that it may not serve as a disease-specific biomarker but may be indicative of general neurodegeneration.This study highlights the diagnostic utility of pTau181, ApoE4 and the Aβ1-42/1-40 ratio for AD and NfL in the CBS-Aβ(-) cases and emphasizes the added value of combined biomarker models for group differentiation. Prospective studies will help validate these findings and refine clinical thresholds.
%K Humans
%K Alzheimer Disease: blood
%K Alzheimer Disease: diagnosis
%K tau Proteins: blood
%K Female
%K Amyloid beta-Peptides: blood
%K Biomarkers: blood
%K Aged
%K Male
%K Peptide Fragments: blood
%K Glial Fibrillary Acidic Protein: blood
%K Middle Aged
%K Neurofilament Proteins: blood
%K Neuroinflammatory Diseases: blood
%K Apolipoprotein E4: blood
%K Aged, 80 and over
%K Corticobasal Degeneration: blood
%K Corticobasal Degeneration: diagnosis
%K Positron-Emission Tomography
%K Apolipoprotein E (ApoE4) (Other)
%K Beta-amyloid 1-40 (Aβ1-40) (Other)
%K Beta-amyloid 1-42 (Aβ1-42) (Other)
%K Glial fibrillary acidic protein (GFAP) (Other)
%K Neurofilament light chain (NfL) (Other)
%K Non-Alzheimer's disease dementia; beta (Other)
%K Phosphorylated tau (pTau) (Other)
%K tau Proteins (NLM Chemicals)
%K Amyloid beta-Peptides (NLM Chemicals)
%K Biomarkers (NLM Chemicals)
%K Peptide Fragments (NLM Chemicals)
%K Glial Fibrillary Acidic Protein (NLM Chemicals)
%K Neurofilament Proteins (NLM Chemicals)
%K Apolipoprotein E4 (NLM Chemicals)
%K amyloid beta-protein (1-42) (NLM Chemicals)
%K neurofilament protein L (NLM Chemicals)
%K GFAP protein, human (NLM Chemicals)
%K amyloid beta-protein (1-40) (NLM Chemicals)
%K MAPT protein, human (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40314736
%2 pmc:PMC12638345
%R 10.1007/s00406-025-02013-z
%U https://pub.dzne.de/record/282550